Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-13
DOI
10.1186/s12933-020-01067-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
- (2020) Ayako Fuchigami et al. Cardiovascular Diabetology
- Exclusion rates in randomized controlled trials of treatments for physical conditions: a systematic review
- (2020) Jinzhang He et al. Trials
- The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study
- (2019) Stuart J. McGurnaghan et al. DIABETOLOGIA
- Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials
- (2019) Jie Liu et al. Cardiovascular Diabetology
- The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus
- (2019) Salvatore Carbone et al. Cardiovascular Diabetology
- Real-world impact of glycated hemoglobin reduction on treatment intensification and glycated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i)
- (2019) Stephen Brunton et al. CURRENT MEDICAL RESEARCH AND OPINION
- Eligibility of patients with type 2 diabetes for sodium‐glucose co‐transporter‐2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry
- (2019) Eric Wittbrodt et al. DIABETES OBESITY & METABOLISM
- Class effect for SGLT-2 inhibitors: a tale of 9 drugs
- (2019) Dario Giugliano et al. Cardiovascular Diabetology
- SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
- (2019) Guntram Schernthaner et al. BMC Endocrine Disorders
- Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice
- (2019) Antonio Nicolucci et al. ADVANCES IN THERAPY
- Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
- (2019) Shih-Chieh Shao et al. Cardiovascular Diabetology
- Class effects of SGLT2 inhibitors on cardiorenal outcomes
- (2019) Aaron Y. Kluger et al. Cardiovascular Diabetology
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion
- (2019) Milton Packer Cardiovascular Diabetology
- Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
- (2019) Lindsay E. Clegg et al. Cardiovascular Diabetology
- How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area
- (2019) Silvia Canivell et al. Journal of Diabetes Research
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
- (2019) DIABETES CARE
- 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
- (2019) Shih-Chieh Shao et al. BMJ Open Diabetes Research & Care
- Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV)
- (2018) Christopher P. Cannon et al. AMERICAN HEART JOURNAL
- Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
- (2018) Lawrence Blonde et al. ADVANCES IN THERAPY
- How Representative are the Patients Included in the CV outcome Trials with SGLT2 Inhibitors of a General Type 2 Diabetes Population? A Large European Observational study
- (2018) K.I. Birkeland et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of MDRD, CKD-EPI, and Cockcroft-Gault equation in relation to measured glomerular filtration rate among a large cohort with diabetes
- (2017) Anke Schwandt et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
- (2016) Christian Sonesson et al. Cardiovascular Diabetology
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
- (2016) Lancet Diabetes & Endocrinology
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
- (2016) Jason H Y Wu et al. Lancet Diabetes & Endocrinology
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2013) Alessandro Liberati ANNALS OF INTERNAL MEDICINE
- Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
- (2008) Peter Gæde et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started